Sutro Biopharma Inc (STRO)
NASDAQ:STRO
STRO Stock Chart & Stats
$25.86
-$0.05(-2.48%)
At close: 4:00 PM EST
$25.86
-$0.05(-2.48%)
Day’s Range― - ―
52-Week Range$5.24 - $27.92
Previous CloseN/A
Volume326.60K
Average Volume (3M)987.85K
Market Cap
$428.43M
Enterprise Value$396.83M
Total Cash (Recent Filing)$141.43M
Total Debt (Recent Filing)$235.21M
Price to Earnings (P/E)―
Beta3.42
Next Earnings
May 13, 2026EPS Estimate
-2.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.29
Shares Outstanding16,567,238
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit3.93
Enterprise Value/Ebitda-3.28
Forecast
1Y Price Target
$26.86Price Target Upside3.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-9.55
Revenue Forecast (FY)$35.50M
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation PotentialInitial Phase 1 STRO-004 data readout may demonstrate lower ocular and bleeding toxicities versus competing tissue-factor–targeting therapy, potentially differentiating the asset on safety.
Platform And Pipeline StrengthProprietary site-specific conjugation and linker technologies support higher dosing and reduced off-target toxicity, underpinning a pipeline that includes STRO-006 and a dual-payload PTK7-targeting program.
Sector Validation From AcquisitionLarge pharma acquisition of an antibody-drug conjugate company validates the sector and may increase strategic interest and valuation for Sutro's ADC platform.
Bears Say
Development And Validation RiskSutro's ADC platform is earlier in clinical development and less technologically validated than the acquired platform, increasing execution risk for advancing lead programs.
Financial And Valuation SensitivityAnalyst notes valuation is sensitive to assumptions about future capital raises, with meaningful clinical uncertainty for key programs creating potential downward pressure if milestones are missed.
Physician Adoption Risk Due To Ocular ToxicityOcular toxicity has historically limited physician adoption of TF-targeting ADCs, and any unresolved eye-safety signals could hinder uptake of STRO-004.
Sutro Biopharma News
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $5.24 and its highest was $27.92 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $428.43M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is May 13, 2026 which is in 30 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Mar 23, 2026. The company reported -$5.29 earnings per share for the quarter, beating the consensus estimate of -$8.163 by $2.873.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -2.63.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 16,567,238 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$5.29 in its last earnings report, beating expectations of -$8.163. Following the earnings report the stock price went up 10.502%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sutro Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.86 (3.87% Upside)
$26.86 (3.87% Upside)
Hedge Fund Trend
Increased
By 26.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
275.30%
Trailing 12-Months
Asset Growth
-55.11%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Stock 12 Month Forecast
Average Price Target
$26.86
▲(3.87% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---